Brain Cancer Trial, Recruiting NCT05274919 Sponsor: Leiden University Medical Center Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT05274919
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older (required for all groups in the trial)
  • People who are scheduled to have a brain MRI scan with a contrast dye injection as part of their regular medical care (Group 1)
  • People who have been diagnosed with a suspected brain tumour called a glioma and are scheduled for a brain MRI as part of their regular medical care (Group 2)
  • People with a confirmed or suspected glioma who have been referred for a tumour biopsy or surgical removal (Group 3)
  • People who have given their written agreement to take part in the trial

Who may not be able to join:

  • People who have a medical reason why they cannot have an MRI scan
  • People who have reduced kidney function, due to the risk of a serious condition called nephrogenic systemic fibrosis (NSF) that can be associated with the contrast dye used in MRI scans
  • People who are pregnant
  • People in Group 1 who are already taking part in another medical protocol that requires scanning to take place during the contrast dye injection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Matthias JP van Osch, Prof Dr Ir, Leiden University Medical Center

Phone: +31657056608

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Leiden University Medical Center
Registry
ClinicalTrials.gov
Start date
16 August 2022
Est. completion
31 March 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Optimized MR protocol; Vessel architecture; Cerebral blood volume; Cerebral blood flow; Transit time parameters; Vascular oxygenation level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov